Gold nanocrystals aim to slow ALS in new trial
NCT ID NCT05299658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is an open-label extension for people with early amyotrophic lateral sclerosis (ALS) who completed a previous placebo-controlled trial. Participants will take a daily oral dose of CNM-Au8, a suspension of gold nanocrystals, to see if it safely slows disease progression. The trial involves 40 participants and focuses on safety and nerve function measures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CNM-Au8 (a suspension of gold nanocrystals taken orally once daily)
What this could lead to
If successful, this could point toward a treatment that slows the progression of ALS, a devastating nerve disease.
What could go wrong
This is a small, early-phase extension study with only 40 participants. It focuses on safety, not proof of effectiveness, and results may not apply to all ALS patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Concord Hospital
Concord, New South Wales, 2139, Australia
-
Neuroscience Research Australia
Randwick, New South Wales, 2031, Australia